secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001558370-24-001524
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Pharma reports record Q4/FY2023 revenue; GAAP net income of $31.9M Q4, $48.2M FY
--------------------------------------------------------------------------------

- Record Q4 revenue $149.7M (+16% YoY); FY revenue $566.8M (+22% YoY).
- GAAP net income $31.9M Q4 ($0.82 diluted) vs loss of $7.2M in Q4 2022; FY net income $48.2M.
- Record adjusted EBITDA $104.2M Q4, $367.0M FY (+38% YoY each).
- Repurchased $75M shares in 2023; new $150M buyback authorized Jan 2024.
- FY 2024 guidance: product revenue $580–595M, adjusted EBITDA $380–395M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000155837024001524/0001558370-24-001524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000155837024001524/coll-20240222x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-001524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer